HOTH Stock Analysis: Buy, Sell, or Hold?
HOTH - Hoth Therapeutics, Inc. Common Stock
$1.36
0.65 (92.01%)
▲
5d:
+126.67%
30d:
+74.36%
90d:
+28.3%
WAIT
LOW Confidence
Analysis Updated: May 27, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Get Alerted When HOTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HOTH is 49.5% above its trading range ($0.91). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HOTH is 49.5% above its trading range ($0.91). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: HOTH is currently trading at $1.36, which is considered extended relative to its 30-day fair value range of $0.51 to $0.91.
Technical Outlook: Technically, HOTH is in a strong downtrend. The price is approaching resistance at $0.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 92.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.00 (+267.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOTH is in a strong downtrend. The price is approaching resistance at $0.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 92.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.00 (+267.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.51 -
$0.91
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+49.5% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+92.0%)
- BULLISH: Trading 267.6% below Wall St target ($5.00)
- WARNING: Recommendation downgraded due to 49.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.51 -
$0.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.54
Resistance Level
$0.70
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.94
Wall Street Target
$5.00
(+267.6%)
Share & Embed Analysis
Last updated: June 17, 2026 4:50 PM ET
Data refreshes hourly during market hours. Next update: 5:50 PM
Data refreshes hourly during market hours. Next update: 5:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 61 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 56 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 61 BUY |
